Joseph G. Pressey · Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
Follow
Article1 min read·Published Jan 2016Older

Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2016 · 1 min read

In brief

In brief

An 18-year-old male with Gorham-Stout disease presenting with lytic rib lesions and refractory pleural effusion achieved dramatic response using combination sirolimus (mTOR inhibitor) and zoledronic acid after interferon failure. This well-tolerated dual-agent approach shows promise for treating this rare life-threatening disorder characterized by lymphatic malformation and progressive bone destruction.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis. Unfortunately, available therapies are not uniformly effective and often carry substantial morbidity. We report an 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and an intractable pleural effusion that responded dramatically to the combination of the mammalian target of rapamycin (mTOR) inhibitor sirolimus and the aminobisphosphonate zoledronic acid after failing interferon therapy. This tolerable therapeutic combination has demonstrated synergism in preclinical cancer models and merits further study in vascular anomalies.

Statements in this article

  1. Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis.

    Established
  2. Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity.

    Established
  3. An 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and intractable pleural effusion responded dramatically to combination therapy with sirolimus and zoledronic acid after failing interferon therapy.

    Research
  4. The combination of sirolimus and zoledronic acid has demonstrated synergism in preclinical cancer models.

    Research

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
Only a few other public items share this field — go deeper there →
GCMD Library — educational content from recorded physician discussions, not medical advice.